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Progression of renal disease and cardiovascular
complications in type II diabetes mellitus have been shown to
correlate with control of blood glucose, lipids, blood
pressure, and smoking. These factors, however, do not
appear to totally explain these diabetic complications. Renal
disease and cardiovascular complications in type II diabetes
are associated with vascular abnormalities and fibrosis, both
of which may occur with impaired fibrinolysis. A
cross-sectional study was therefore performed in 107 type II
diabetic patients recruited from the Denver Metropolitan
Area to examine the effect of impaired fibrinolysis, as
assessed by the ratio of plasminogen activator inhibitor
(PAI-1) to tissue-type plasminogen activator (t-PA). With
urinary albumin excretion (UAE) as a risk factor for both renal
disease progression and cardiovascular complications, the
patients were analyzed with respect to UAE less than and
greater than 1 gm/day. The age, blood glucose, hemoglobin
A1C, duration of diabetes, lipids, body mass index, and
smoking were no different between the groups. As expected,
the group with greater UAE had worse renal function, the
serum creatinine (1.9870.24 vs 1.2170.05 mg/dl, Po0.001)
and creatinine clearance (55.576.0 vs 76.872.7 ml/min,
Po0.001) were significantly different. The type II diabetic
patients with greater UAE exhibited significantly higher
PAI-1/t-PA (2.4370.26 vs 1.8570.07, Po0.03). The past
history of cardiac complications was also higher (87.5 vs
72.3%, Po0.07) in the diabetic patients with more impaired
fibrinolysis and greater UAE. Thus a prospective, randomized
clinical trial in type II diabetes with PAI-1 inhibitors is needed.
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It is well established that vascular injury and cardiovascular
diseases are the leading cause of death in diabetic patients1,2
and diabetes is the major cause of end-stage renal disease.3
Elevated urinary albumin excretion (UAE) is associated with
increased risk of atherosclerotic cardiovascular mortality and
progression of diabetic nephropathy in type II diabetes
patients.4–6 The pathophysiological mechanisms behind this
observation are not clear. One of the critical responses to
vascular injury is the activation of the plasminogen activation
(PA) system including tissue-type (t-PA) and urinary-type
plasminogen activator (u-PA), which convert plasminogen
to plasmin. Plasmin in turn degrades fibrin and several
extracellular matrix proteins. Fibrin deposition is an
important factor in the development of vascular disorders
such as atherosclerosis, and the accumulation of extracellular
matrix proteins is a hallmark of renal fibrosis. By inhibition
of t-PA and u-PA, as well as direct inhibition of plasmin,
plasminogen activator inhibitor (PAI-1) may play an
important role in the regulation of intravascular fibrin
deposition, thrombosis, atherosclerosis, as well as renal
fibrosis.7–9 The resultant fibrosis and vascular injury in the
kidney may be critical in the glomerular capillary leakage of
proteins and resultant albuminuria. PAI-1 also can exert
plasmin-independent effects on fibrin homeostasis by its
capacity to react with other proteases such as activated
protein C.10 In addition to its role in the regulation of
vascular fibrinolysis and fibrin deposition, PAI-1 exerts an
effect on vascular smooth muscle proliferation.7 The effects
of PAI-1 on vascular pathology could be a possible link
between albuminuria and cardiovascular diseases, as well as
kidney disease progression in diabetic patients. The present
study was therefore undertaken to examine the relationship
between the ratio of PAI-1 and t-PA, as an index of
fibrinolytic activity, UAE, and the progression of renal
disease.
RESULTS
Characteristics of the study population
The clinical and biochemical characteristics of the total study
population are shown in Table 1. The patients’ average age
was 65.2 years; and they had diabetes for a mean of 17.4
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years. They were obese and mean creatinine clearance was
72 ml/min and UAE was increased. Their blood glucose
control was not optimal as assessed by hemoglobin A1C.
A comparison of the patients with a UAE less than or
equal to 1000 mg/day vs greater than 1000 mg/day are shown
in Table 2. The patients were comparable with respect to age,
blood glucose, hemoglobin A1C, duration of diabetes,
plasma lipids, systolic and diastolic blood pressure, and
smoking. As expected, the diabetic patients with UAE
greater than 1 gm/day had significantly higher serum
creatinine concentration and lower creatinine clearances
(Figure 1a and b). With respect to impaired fibrinolysis in
the diabetic patients, the PAI-1/tPA ratio was significantly
higher in the patients with greater UAE (Figure 2). Over a 7-
year mean follow-up, the rise in serum creatinine was larger
in the diabetic patients with UAE 41000 (0.8270.21 mg/
day) compared with patients with UAE p1000 mg/day
(0.0770.03, P¼ 0.0002).
DISCUSSION
Obesity and type II diabetes mellitus are increasing in
epidemic proportions in the US.11–13 Cardiovascular compli-
cations lead to approximately 50–70% of mortality in type II
diabetes1,2,14 and presently nearly 50% of new patients with
end-stage renal disease are because of diabetes.3 Results from
prospective randomized studies have demonstrated that, in
addition to control of blood glucose, aggressive antihyper-
tensive therapy with a blood pressure (BP) goal of less than
130/80 mm Hg and inhibition of renin–angiotensin–aldoster-
one system decreases cardiovascular morbidity and mortality,
stroke, diabetic retinopathy and diabetic nephropathy, and
overall deaths.15–18 Although risk surveillance of BP, hemo-
globin A1C, lipids, and smoking is important in type II
diabetic patients, an increased rate of UAE also has been
shown to correlate with cardiovascular mortality19,6 and
progression of renal disease.
An increase in UAE indicates glomerular capillary albumin
leakage, and also has been proposed to be an index of
vascular damage throughout the body. While glomerular
capillary leakage of albumin can be collected as urine,
quantitation of interstitial albumin, as an index of capillary
damage, is obviously not possible in the cardiovascular,
retinal, and neurological systems. Thus, increased UAE has
been suggested to reflect diffuse endothelial injury through-
out the body.
The present study in 107 hypertensive type II diabetic
patients examined another potential risk factor for cardio-
vascular complications and progression of renal disease,
namely the activity of the fibrinolytic system. There is
substantial evidence that thrombosis is an important
pathogenic factor in myocardial infarctions and strokes.
PAI-1 is important in modulating fibrinolysis and
proteolysis. The conversion of plasminogen to plasmin
with resultant fibrinolysis is stimulated by t-PA. There-
fore, an increase in the PAI-1/t-PA ratio is as an index of
impaired fibrinolysis.
We hypothesized that the impaired fibrinolysis in our type
II diabetic patients would be significantly increased in those
diabetic patients with greater UAE. This was indeed the case.
Moreover, the patients with impaired fibrinolysis had
diminished renal function and a greater loss of function
over a 7-year follow-up period. The relationship between
impaired fibrinolysis and proteolysis in those type II diabetic
patients with the greater UAE was independent of any
difference in age, blood glucose, duration of diabetes, blood
lipids, systolic or diastolic blood pressure, and smoking.
Activation of the renin–angiotensin–aldosterone system in
type II diabetic patients may also be involved in the
inhibition of fibrinolysis. Angiotensin II can directly increase
PAI-1 concentrations20–22 and also indirectly stimulate PAI-1
level via an increase in TGF beta (TGF-b).23 TGF-b, which is
a potent profibrotic molecule, not only increases PAI-1 level
but also induces extracellular matrix synthesis and fibrosis.24
Furthermore, a high dose of an angiotensin II type 1 receptor
antagonist attenuated glomerulosclerosis via a decrease in
PAI-1 level.25 As the patients in the present study were all
receiving the angiotensin-converting inhibitor, enalapril, any
effect of angiotensin II on PAI-1 and TGF-b would be
attenuated, but probably not abolished.
The combination of decreased extracellular matrix
degradation secondary to diminished fibrinolysis and pro-
teolysis combined with increased extracellular matrix synth-
esis induced by TGF-b would be expected to increase tissue
fibrosis. Cardiac fibrosis and renal interstitial fibrosis are
hallmarks of diabetes-related cardiomyopathy and nephro-
pathy, respectively. Thus, increased PAI-1/t-PA ratio may
not only increase cardiovascular mortality by enhanced
thrombosis but also by increasing cardiac fibrosis. The
impaired fibrinolysis may also increase renal fibrosis and thus
contribute to the progression of diabetic nephropathy. It has
Table 1 | Characteristics of the study population
N=107 Mean7s.e.
Age (years) 65.1870.76
BMI (kg/m2) 32.5770.53
Systolic BP (mm Hg) 142.7071.81
Diastolic BP (mm Hg) 80.8770.81
Glucose (mg/dl) 186.7176.59
Total cholesterol (mg/dl) 202.0474.19
TG (mg/dl) 219.08717.5
HDL (mg/dl) 40.3771.02
LDL (mg/dl) 120.4373.27
VLDL (mg/dl) 34.5771.85
HbA1C (%) 8.7570.14
Serum Cr (mg/dl) 1.3970.07
Cr clearance (ml/min) 71.9972.64
Duration of diabetes (years) 17.3870.76
PAI-1 (IU/ml) 21.1970.13
t-PA (IU/ml) 11.5670.83
UAE (mg/min) 628.127139.02
BMI, body mass index; BP, blood pressure; TG, triglyceride; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein;
HbA1C, glycosylated hemoglobin; Cr, creatinine; LVMI, left ventricular mass index;
PAI-1, plasminogen activator inhibitor type 1; t-PA, =tissue-type plasminogen
activator; UAE, urinary albumin excretion; s.e.=standard error.
1900 Kidney International (2006) 69, 1899–1903
o r i g i n a l a r t i c l e M Kamgar et al.: Diabetes, PAI-1, urinary albumin excretion
been shown that diabetic mice null for PAI-1 (PAI-1/)
showed less albuminuria and TGF-b expression than wild-
type mice (PAI-1þ /þ ).26
With respect to renal progression, there was a significantly
higher serum creatinine concentration, as an index of kidney
function in those patients with higher UAE and impaired
fibrinolysis. Moreover, a retrospective evaluation also was
undertaken to examine the incremental changes in serum
creatinine concentration over a 7-year follow-up period in
relationship to the fibrinolytic ratio. A larger increment in
serum creatinine was observed in those patients with the
greater UAE and higher fibrinolytic ratio. With impaired
fibrinolyis, intravascular fibrin deposition may occur and
contribute to intimal hyperplasia in the vasculature, a
hallmark of diabetic cardiomyopathy and nephropathy. This
vascular perturbation in diabetic patients also could increase
vascular permeability and thereby contribute to the increased
UAE. The endothelial dysfunction in these diabetic patients
could be the common pathway for both the increased PAI-1
and UAE.
It should be recognized that there are several studies that
have shown a correlation between UAE and PAI-1. These
studies have been performed in healthy males with an average
age of 58 years,27 patients with essential hypertension28 and
type II diabetes.29,30 In these publications, a relationship
between impaired fibrinolysis and progression of renal disease
has not been studied. No measurement of renal function (i.e.
serum creatinine or creatinine clearance) was included in these
papers27–29 except in one of the publications.30 In this study30
however, creatinine clearance was reported in only diabetic
patients with microalbuminuria and no correlation between
UAE and PAI-1 was found. No diabetic patient with larger
amounts of UAE was included in the study.
Table 2 | Characteristics of patients with UAE p1000 mg/day vs UAE 41000 mg/day
UAE p1000 mg/day (N=83) UAE 41000 mg/day (N=24)
Variable Mean7s.e. Mean7s.e. P-value
PAI/t-PA (ng/ml) 1.8570.07 2.4370.26 0.0314
t-PA (ng/ml) 11.870.56 10.670.95 0.4818
PAI (ng/ml) 20.970.99 22.371.46 0.3283
HbA1c (%) 8.870.16 8.670.31 0.3492
Glucose (mg/dl) 183.977.23 196.3715.56 0.5274
HDL (mg/dl) 40.370.96 40.873.14 0.3901
LDL (mg/dl) 118.473.52 127.978.10 0.2703
VLDL (mg/dl) 34.172.12 36.273.89 0.4739
Cholesterol (mg/dl) 199.274.81 211.978.39 0.1389
Triglycerides (mg/dl) 209.7718.99 251.1742.17 0.2298
Serum creatinine concentration (mg/dl) 1.270.05 1.9870.24 0.0010
Creatinine clearance 76.872.73 55.575.96 0.0015
Average change in SCR over 6.8 years 0.0970.03 0.8270.21 0.000
Change rate in SCR (mg/dl/per/year) 0.0170.008 0.1170.035 0.0086
Weight (kg) 100.572.20 89.573.37 0.0109
Height (cm) 173.571.14 172.571.93 0.5366
BMI (kg/m2) 33.370.60 30.170.98 0.0099
SBP (mm Hg) 14172.00 14874.01 0.2618
DBP (mm Hg) 8170.91 8071.80 0.8143
Diabetes duration (years) 17.170.89 18.471.50 0.2930
Age (years) 65.170.86 65.371.67 0.9851
Cardiovascular disease 60/83 (72.3%) 21/24 (87.5%) 0.0708
Smoking 52/83 (62.7%) 16/24 (66.7%) 0.7188
Note: Comparison of continuous variables was performed using Wilcoxon Sign-Rank test. Comparison of cardiovascular disease was performed using Fisher’s Exact test.
BMI, body mass index; SBP, blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein;
HbA1C, glycosylated hemoglobin; PAI-1, plasminogen activator inhibitor type 1; t-PA, =tissue-type plasminogen activator; UAE, urinary albumin excretion; s.e.=standard error.
Smoking defined as greater than 100 cigarattes.
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Figure 1 | Relationship between UAE and renal function.
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Figure 2 | Impaired fibrinolysis in type II diabetic patients with
UAE greater than 1 gm/day.
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Lastly, it should be mentioned that a new potent inhibitor
of fibrinolysis, the thrombin-activatable fibrinolysis inhi-
bitor, has been identified and found to be higher in type II
diabetic patients with microalbuminuria as compared to
those diabetic patients with normoalbuminuria.30 This
inhibitor of fibrinolysis is in need of further study in diabetic
patients with respect to cardiovascular disease and renal
complications.
Thus, an impairment of fibrinolysis and proteolysis
associated with a decrease in plasmin generation in hyper-
tensive type II diabetic patients may predispose to thrombo-
sis and fibrosis and thereby increase cardiovascular and renal
morbidity and mortality. The numerous interactions that
may occur in type II diabetic patients secondary to impaired
fibrinolysis and proteolysis and thereby contribute to diabetic
cardiomyopathy and nephropathy are shown in Figure 3. The
results of the present study indicate that in addition to
BP, smoking cessation, blood glucose and lipid control,
impaired fibrinolysis, and proteolysis may be important
contributors to diabetic cardiovascular and renal complica-
tions. A prospective randomized study is needed to test the
hypothesis that inhibition of PAI-1 will diminish diabetic
cardiovascular and renal complications.
MATERIALS AND METHODS
From the hypertensive cohort of the Appropriate Blood Pressure
Control Trial, 107 type II diabetic patients with albuminuria (UAE
420 mg/min) residing in the greater Denver metropolitan region
were enrolled in the present study to examine fibrinolytic activity.
All patients were hypertensive (BP4140/90 mm Hg) at the time of
randomization for the Appropriate Blood Pressure Control Trial
study to nisoldipine or enalapril. However, at the time of present
study, all patients were on enalapril, because the patients on
enalapril therapy were shown to have fewer myocardial infarctions
during the first 4 years of the study than those patients on
nisoldipine.31 Patients in whom the assigned BP lowering goal was
not achieved with the initial double-blind therapy received
additional open-label antihypertensive therapy (atenolol and
hydrochlorothiazide) as needed. Detailed description of patients’
characteristics at the start of the Appropriate Blood Pressure Control
Trial, including eligibility criteria, target and achieved BP, baseline
kidney function, and kidney function during the 5-year Appropriate
Blood Pressure Control Trial study have been published pre-
viously.32,33
Type II diabetes was diagnosed according to the criteria based on
the World Health Organization report of 1985,34 which followed the
National Diabetes Group criteria of 1979.35 Three BP measurements
were taken at 2-min intervals in the sitting position. A standard
mercury sphygmomanometer was used by trained nurses.
UAE was measured for individual patients on three separate
occasions consisting of one 24-h urine collection and two overnight
collections. The following formula was used to calculate the mean of
UAE: albumin concentration (mg/dl) urine volume (ml)/collec-
tion duration (min). UAE was categorized by stage: microalbumi-
nuria (20–200 mg/min), overt albuminuria (4200 mg/min).
To calculate creatinine clearance values, patient’s weight, urine,
and serum creatinine were measured at the same time. The
following formula was used to calculate creatinine clearance:
creatinine clearance¼ 4.014 ((urine creatinine concentration
urine volume)/(serum creatinine concentration collection dura-
tion height0.725weight0.425)).
For PAI-1 and t-PA assays, blood samples were obtained at the
Colorado Prevention Center and measured at the University of Texas
Medical Center, Houston, Texas using standard methodology.36
Because the balance between PAI-1 and t-PA is important in regula-
tion of fibrinolytic system, PAI-1/t-PA ratio has been considered as
an indicator of fibrinolytic system status. Other laboratory data were
analyzed using a central laboratory: LabCorp, Denver, CO, USA.
Fisher’s exact test comparison of smoking was performed using w2
test of independence.
Statistical methods
Data were analyzed using SAS 9.1. Numerical data are presented as
means and standard error of means. Comparisons in continuous
variables were performed using non-parametric, Wilcoxon Sign-
Rank tests. Presence of cardiovascular disease was tested using w2 test
of Independence. P-values less than 0.05 were considered significant.
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